Skip To Main Content
Jake Cole on Muck Rack

Jake Cole

Atlanta
As seen in: Slant Magazine, MSN, MSN Australia, Yahoo Entertainment, Yahoo Canada, Los Angeles Times en Espanol, Newsweek, Flipboard, IndieWire, The Mercury News, Metacritic and
Like the phoenix from the ashes. Writing at @Slant_Magazine, @hyperallergic, others.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jake

Contact Jake, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Precision oncology is redefining cancer treatment

|
By Jake Cole
| MSN Verified
; ; ; ; Continue reading More for You Continue reading More for You
Open in Who Shared View Duplicates (490) Issue with article?

Manufacturing strategy is becoming a competitive edge for product startups

|
By Jake Cole
| MSN Verified
Launching a physical product has never been more accessible. Digital marketplaces, creator platforms, and social media have made it possible for entrepreneurs to build national audiences without traditional retail distribution. The U.S. Small Business Administration (SBA) reports that Americans filed more than 21 million new business applications between 2021 and 2024, reflecting one of the strongest periods of entrepreneurial activity in recent history.
Open in Who Shared View Duplicates (3) Issue with article?

Why breakthrough therapies in biotech are losing the commercial battle

|
By Jake Cole
| MSN Verified
Biotech has entered an era of extraordinary scientific ambition, from highly targeted oncology treatments to advanced gene and cell therapies designed around individual patient needs. In recent months, the BBC has reported the launch of the new cancer therapy Zi-MA4-1, while the FDA announced the approval of new cellular and gene therapy products.
Open in Who Shared Issue with article?
See all 811 licensed articles (820 Total)